This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
GE Says Goodbye to the Dow
by Nimah Quadri
General Electric (GE), the American multinational conglomerate, and the last original company from the 1986 Dow, is no longer on the 30-stock index.
Humana, Walgreens Team Up to Provide Better Senior Care
by Zacks Equity Research
Humana (HUM) ties up with Walgreens to provide better primary care and other services to seniors of the Kansas City Community.
Walgreens Boots' Retail Pharmacy Strong Despite Several Woes
by Zacks Equity Research
Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.
Stock Market News For Jun 20, 2018
by Zacks Equity Research
Markets ended sharply lower on Tuesday, as trade war fears escalated once again.
Dow Bids Adieu to GE, Welcomes Walgreens
by Nalak Das
The General Electric/Walgreens replacement will reduce the weight of industrial sector within the Dow 30 index and increase the weight of the consumer goods sector.
Can Rite Aid's (RAD) Strategies Reverse Earnings Trend in Q1?
by Zacks Equity Research
Rite Aid's (RAD) prospects look bright, owing to the pending acquisition, solid fiscal 2019 outlook and other strategies. But we remain skeptical about near-term results due to its dismal past trends.
Top Analyst Reports for Schlumberger, Walgreens Boots & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Schlumberger (SLB), Walgreens Boots (WBA) and BNY Mellon (BK).
Hologic's New Panther Fusion System Gets Health Canada Nod
by Zacks Equity Research
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
Is Walgreens Boots (WBA) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Walgreens Boots (WBA) stock is a good choice for value-oriented investors right now from multiple angles.
Express Scripts' Inside Rx to Cut Medical Costs for the Aged
by Zacks Equity Research
Express Scripts (ESRX) keeps its commitment towards patient benefit management through subsidiary Inside Rx.
Walgreens Boots (WBA) Down 2.4% Since Last Earnings Report
by Zacks Equity Research
Walgreens Boots (WBA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Are Walgreens and CVS Shares Surging Today?
by Ryan McQueeney
Shares of several major pharmaceutical retailers--including Walgreens (WBA) and CVS Health (CVS)--surged in afternoon trading Monday after reports emerged that e-commerce behemoth Amazon (AMZN) has shelved its plan to sell prescription drugs to doctors and hospitals.
Bear of the Day: Signet Jewelers Limited (SIG)
by David Borun
Retail Jewelry Stores are Badly Beaten by the Trend Toward Online Sales
The Zacks Analyst Blog Highlights: Mastercard, Petrobras, Walgreens Boots Alliance, Microchip and Carnival
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: Mastercard, Petrobras, Walgreens Boots Alliance, Microchip and Carnival
Top Stock Reports for Mastercard, Petrobras & Walgreens Boots Alliance
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Petrobras (PBR) and Walgreens Boots Alliance (WBA).
Company News For Mar 29, 2018
by Zacks Equity Research
Companies in the news are: LULU,RH,WBA,FB
Walgreens Boots (WBA) Tops Q2 Earnings, Revenues Estimates
by Zacks Equity Research
Walgreens Boots (WBA) rides high in Q2 on strength in Retail Pharmacy USA division and Pharmaceutical Wholesale division.
Should You Buy Walgreens Boots (WBA) Ahead of Earnings?
by Zacks Equity Research
Walgreens Boots (WBA) witnesses improvement in sales at the Retail Pharmacy International segment.
LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm
by Zacks Equity Research
The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.
Should Value Investors Pick Walgreens Boots Alliance (WBA) Stock?
by Zacks Equity Research
Is Walgreens Boots Alliance (WBA) a great pick from the value investor's perspective right now? Read on to know more.
Express Scripts, Walgreens Tie Up to Cut Specialty Drug Price
by Zacks Equity Research
Express Scripts (ESRX) expands group purchasing effort with Walgreens Boots Alliance to simplify supply chains and make specialty drugs affordable.
Rite Aid (RAD) on Track with Asset Sale: Is it Aiding Stock?
by Zacks Equity Research
Rite Aid Corporation (RAD) is on track with the process of transferring stores and related assets to Walgreens under its amended and restated asset purchase agreement.
Rite Aid (RAD) Soars Too High Too Fast: Is This Justified?
by Zacks Equity Research
Rite Aid Corporation (RAD) stock seems to have gained solid momentum following the recent sale of stores to Walgreens. However, the company has been facing issues with dismal sales, heavy debt burden and strained margins.
Top Stock Reports for PepsiCo, Walgreens Boots & EOG Resources
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Walgreens Boots (WBA) and EOG Resources (EOG).